Reymundo Lozano

May 07, 2015

Reymundo Lozano has joined the clinical and strategic advisory board of Courtagen Life Sciences. He is a pediatric geneticist and researcher, specializing in intellectual disability and autism spectrum disorder.

More Like This

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Executive Vice President and Chief Financial Officer at Meridian Bioscience, Melissa Lueke, will retire from her position effective January 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of Corporate Development to the position of EVP, CFO, and Principal Financial Officer, also effective January 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior Vice President, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She previously held numerous executive positions during an investment banking career with Morgan Stanley, including managing director head of West Coast Healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as Chief Scientific Officer and head of research and development. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of research and development for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Dec 10, 2018

Cynthia Collins

Cynthia Collins has joined the board of directors of Editas Medicine. Most recently, she was the CEO of Human Longevity. Prior to that, she was CEO/GM of General Electric's Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. Before that, she was president and CEO of GenVec, and prior to that, group vice president of the Cellular Analysis Business of Beckman Coulter. Collins holds a BS degree in microbiology from the University of Illinois, Urbana, and an MBA from the University of Chicago Booth School of Business.

Dec 10, 2018

Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective January 1, 2019. Anderson is currently CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy. Anderson holds a master of science degree in management and chemical engineering from MIT.

Dec 10, 2018

Prahlad Singh

Prahlad Singh has been appointed president and COO of PerkinElmer, effective Jan. 1, 2019. Singh will be responsible for the Discovery and Analytical Solutions and the Diagnostics operating divisions. PerkinElmer said the change is being made to "better facilitate synergies across the businessess to identify incremental growth opportunities, create operating efficiencies, and most importantly, accelerate the pace of innovation across the company." He joined PerkinElmer in 2014 as president of the diagnostics business and was elected an officer in 2016 and executive vice president in 2016. Prior to joining the firm, Singh was GM of GE Healthcare's women's health business, and before that he held senior executive level positions in strategy, business development, and M&A at GE and at Philips Healthcare. 

Dec 10, 2018

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

Dec 07, 2018

E. Robert Wassman

NeuroPointDx, a division of Stemina Biomarker Discovery, has appointed E. Robert Wassman as its medical director. Wassman has acted as chief medical officer (CMO) for several companies in the genetic testing, biomarker discovery, and diagnostic development space. He previously served as CMO of Lineagen from 2015 to 2017. Before that, he served as CMO at Rosetta Genomics from 2012 to 2015. Wassman has also previously served as CMO at other companies in the personalized medicine space over the past 35 years, including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen. 

Dec 07, 2018

Caroline Loew, Stanley Lapidus, Robert Langer

Glympse Bio has appointed Caroline Loew as the firm's president and CEO. Loew previously served as VP, heading of R&D strategy and planning at Bristol-Myers Squibb. In addition, she has served in senior roles at Merck and phRMA over the past 20 years, where she led teams in drug development, regulatory policy, market access, and commercial. 

Glympse has also appointed Stanley Lapidus as the firm's chairman and Robert Langer to the firm's board of directors. Lapidus has been the founding CEO of four medical technology companies, including Cytyc, Exact Sciences, Helicos, and SynapDx.

Dec 06, 2018

Hilde Furberg, Guido Oelkers

Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Hilde has previously worked at companies including Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.

In addition, Blueprint has appointed Guido Oelkers as a senior advisor to the firm. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. Previously, he served in roles including CEO of BSN Medical, CEO of Gambro, CEO of Invida, and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis. 

Dec 06, 2018

Bradley Cole

Castle Biosciences has appointed Bradley Cole to its board of directors. Cole currently serves as Genomic Health's CFO. In addition, Cole served as both chief operating officer and CFO at the firm. Previously, Cole served as VP of finance and business development for the Endovascular Solutions Group at Guidant. Prior to that, he served as VP and general manager of the vascular surgery business unit of Guidant. Previously, he served as CFO at Endovascular Technologies until it was acquired by Guidant in 1997. Before Endovascular, he served as CFO at Applied Biosystems until 1994. 

Nov 30, 2018

Stevan Knezevich

DermTech has appointed Stevan Knezevich to its scientific advisory board. Knezevich has a PhD in pathology and laboratory medicine from the University of Vancouver, B.C., and a MD from the University of Toronto. 

Nov 28, 2018

Joseph Khoury

Angle has appointed Joseph Khoury to its scientific advisory board. Khoury currently serves as a tenured professor of pathology and laboratory medicine at the University of Texas MD Anderson Cancer Center.

Nov 28, 2018

Benjamin Reed, James Fullerton-Batten, Nick Ash, Matt Pomroy

Epistem has completed its board appointments: Benjamin Reed will join as commercial director — he had previously served as Epistem's pharmacogenomics business development director; James Fullerton-Batten joins the board from Concept Life Sciences, where he served as finance director; Nick Ash joins the board from Source BioScience, where he served as CEO; and Matt Pomroy joins the board as a non-executive investor representative from Foresight Group.


Nov 26, 2018

Reginald Seeto

CareDx has appointed Reginald Seeto to the newly created role of president and chief business officer. Seeto has 20 years of experience in commercial operations, corporate development, and strategy, most recently serving as chief operating officer at Ardelyx. He has also worked at AstraZeneca/Medimmune and was a member of the MedImmune executive team. His responsibilities there included leading corporate development and strategy, global strategic marketing, and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. Before AstraZeneca, Seeto held positions at Organon Biosciences and at McKinsey.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.